Clotilde Allavena1, Christine Katlama2, Laurent Cotte3, Pierre Marie Roger4, Pierre Delobel5, Antoine Cheret6, Claudine Duvivier7, Isabelle Poizot-Martin8, Bruno Hoen9, André Cabie10, Arnaud Cheret11, Rima Lahoulou11, François Raffi1, Pascal Pugliese4. 1. a Infectious Diseases, CHU Hôtel Dieu University Hospital , Nantes , France ; 2. b Infectious Diseases, AP-HP Pitié Salpétrière Hospital , Paris , France ; 3. c Infectious Diseases, Hôpital Croix-Rousse, Hospices Civils de Lyon , Lyon , France ; 4. d Infectious Diseases, CHU de l'Archet , Nice , France ; 5. e Infectious Diseases, CHU Toulouse , Toulouse , France ; 6. f Infectious Diseases, CHU DRON , Tourcoing , France ; 7. g Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Necker-Pasteur Infectious Diseases Center, Descartes University, Sorbonne Paris Cité , EA7327 , IHU Imagine , Paris , France ; 8. h Infectious Diseases, Aix-Marseille University , APHM Sainte-Marguerite, Department of Immuno-hematology , Inserm U912 (SESSTIM) , Marseille , France ; 9. i Infectious Diseases, CHU Besançon , Besancon , France ; 10. j Infectious Diseases, CHU de Martinique , Inserm CIC1424 , France ; 11. k Janssen, Issy les Moulineaux , France.
Abstract
OBJECTIVES: Etravirine (ETR) was approved in France in September 2008 and is used in combination with a boosted protease inhibitor (bPI) and other anti-retrovirals (ART) in HIV-infected pre-treated patients. This study aimed to report in a real-life setting the efficacy and tolerability of ETR-based regimens and factors associated with virological response. METHODS: The study population included all treatment-experienced patients who initiated an ETR-based regimen between September 2008 and July 2013 from the French Dat'AIDS cohort. Analyses were performed in ART-experienced patients starting ETR after virological failure (VF) or as a maintenance therapy (MT), with or without bPI. RESULTS: A total of 2006 patients (VF, n = 1014 (51%); MT, n = 992 (49%)) were included. At M12, the proportion of patients with HIV RNA < 50 copies/ml was 71.7% (72.0% and 71.1% with or without bPI) in the VF group and 90.5% (85.0% and 92.3% with or without bPI) in the MT group, without significant differences regarding the use of bPI. ETR was discontinued in 8.8% of patients for adverse events in 23.9% of cases (21.5% in VF, 29.5% in MT), treatment failure in 15.2% (16.2% in VF, 7.4% in MT) or simplification in 5.4% (4.6% in VF, 7.4% in MT). In the VF group, factors associated with virological response were a longer duration of HIV infection (OR = 2.7; p < 0.001) and baseline HIV RNA < 5 log10 copies/mL (OR = 2.1; p = 0.002). CONCLUSION: This study shows that in ART-experienced patients ETR is well tolerated with a high efficacy when combined with other active drugs, even when the regimen does not include a bPI.
OBJECTIVES:Etravirine (ETR) was approved in France in September 2008 and is used in combination with a boosted protease inhibitor (bPI) and other anti-retrovirals (ART) in HIV-infected pre-treated patients. This study aimed to report in a real-life setting the efficacy and tolerability of ETR-based regimens and factors associated with virological response. METHODS: The study population included all treatment-experienced patients who initiated an ETR-based regimen between September 2008 and July 2013 from the French Dat'AIDS cohort. Analyses were performed in ART-experienced patients starting ETR after virological failure (VF) or as a maintenance therapy (MT), with or without bPI. RESULTS: A total of 2006 patients (VF, n = 1014 (51%); MT, n = 992 (49%)) were included. At M12, the proportion of patients with HIV RNA < 50 copies/ml was 71.7% (72.0% and 71.1% with or without bPI) in the VF group and 90.5% (85.0% and 92.3% with or without bPI) in the MT group, without significant differences regarding the use of bPI. ETR was discontinued in 8.8% of patients for adverse events in 23.9% of cases (21.5% in VF, 29.5% in MT), treatment failure in 15.2% (16.2% in VF, 7.4% in MT) or simplification in 5.4% (4.6% in VF, 7.4% in MT). In the VF group, factors associated with virological response were a longer duration of HIV infection (OR = 2.7; p < 0.001) and baseline HIV RNA < 5 log10 copies/mL (OR = 2.1; p = 0.002). CONCLUSION: This study shows that in ART-experienced patientsETR is well tolerated with a high efficacy when combined with other active drugs, even when the regimen does not include a bPI.
Authors: Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Valérie Potard; Cécile Goujard; Marc Antoine Valantin; Jean Marc Lacombe; Rima Lahoulou; Arnaud Chéret; Pierre Marie Girard; Dominique Costagliola Journal: BMC Infect Dis Date: 2018-07-11 Impact factor: 3.090